Rapport Therapeutics, Inc.
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027